

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Practitioner's Docket No. MPM00-018P2R
(703) 308-6778

PATENT

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on March 17, 2005


Signature
Simonne Corriveau

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

"Fee Address" Indication Form	(1 page)
Statement Under 37 CFR 3.73(b)	(1 page)
Notice of Recordation of Assignment Document	(1 page)
Copy of Assignment signed by Glenn Barnes	(2 pages)
Copy of Assignment signed by Joanne Meyer	(2 pages)

Total Pages (8 pages)
(Including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OIPF/JCWS

APR 22 2005

RECEIVED

PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Millennium Pharmaceuticals, Inc.Application No./Patent No.: 6,797,475 Filed/Issue Date: September 24, 2004Entitled: ASSAY FOR AGENTS WHICH ALTER G-PROTEIN COUPLED RECEPTOR ACTIVITYMillennium Pharmaceuticals, Inc., a a Delaware corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 013116, Frame 0900, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Jean M. Silveri
Signature

March 17, 2005

Date

Jean M. Silveri

Printed or Typed Name

617-679-7336

Telephone Number

Associate General Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES
PATENT AND
TRADEMARK OFFICE

COPY

SEPTEMBER 25, 2002

LAHIVE & COCKFIELD, LLP
DEANN F. SMITH, ESQ.
28 STATE ST.
BOSTON, MA 02109

PTAS

Under Secretary of Commerce For Intellectual Property and
Director of the United States Patent and Trademark Office
Washington, DC 20231
www.uspto.gov



102170813A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 07/22/2002 ✓

REEL/FRAME: 013116/0900 ✓
NUMBER OF PAGES: 5

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:
BARNES, GLENN ✓

DOC DATE: 05/28/2002

ASSIGNOR:
MEYER, JOANNE M.

DOC DATE: 05/28/2002

ASSIGNEE:
MILLENNIUM PHARMACEUTICALS, INC. ✓
75 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139

SERIAL NUMBER: 10071411
PATENT NUMBER:

FILING DATE: 02/07/2002 ✓
ISSUE DATE:

TONYA LEE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

ASSIGNMENT

We, Glenn Barnes of Haverhill, Massachusetts and Joanne Meyer of Marlborough, Massachusetts in consideration of One Dollar and other valuable consideration paid to us by:

MILLENNIUM PHARMACEUTICALS, INC.

a corporation of Delaware, having its principal place of business at 75 Sidney Street, Cambridge, Massachusetts 02139, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said:

MILLENNIUM PHARMACEUTICALS, INC.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in:

DETECTION OF POLYMORPHISMS IN THE HUMAN 5-LIPOXYGENASE GENE

described in an application:

- ☐ executed by us of even date herewith and about to be filed
☒ U.S. Serial No. 10/071,411 filed on February 7, 2002

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said corporation, with specifications and claims in such form as shall be approved by the counsel of said corporation and to vest and confirm in said corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said corporation, its successors and assigns.

WITNESS my hand and seal this 28th day of MAY, 2002.

By: 

Glenn Barnes

Commonwealth of Massachusetts)

County of Suffolk) s.s.

Then personally appeared the above named Glenn Barnes and acknowledged the foregoing instrument to be his/her free act and deed, before me, this 28 day of May, 2002.


 Notary Public

My commission expires: May 1, 2009


 NASIM G. MEMON
 Notary Public

MRI-021

WITNESS my hand and seal this _____ day of _____, 2002.

By: _____
Joanne MeyerCommonwealth of Massachusetts)
) s.s.
County of)

Then personally appeared the above named Joanne Meyer and acknowledged the foregoing instrument to be his/her free act and deed, before me, this _____ day of _____, 2002.

Notary Public
My commission expires: _____

ASSIGNMENT

We, Glenn Barnes of Haverhill, Massachusetts and Joanne Meyer of Marlborough, Massachusetts in consideration of One Dollar and other valuable consideration paid to us by:

MILLENNIUM PHARMACEUTICALS, INC.

a corporation of Delaware, having its principal place of business at 75 Sidney Street, Cambridge, Massachusetts 02139, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said:

MILLENNIUM PHARMACEUTICALS, INC.

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in:

DETECTION OF POLYMORPHISMS IN THE HUMAN 5-LIPOXYGENASE GENE

described in an application:

- ☐ executed by us of even date herewith and about to be filed
☒ U.S. Serial No. 10/071,411 filed on February 7, 2002

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said corporation, with specifications and claims in such form as shall be approved by the counsel of said corporation and to vest and confirm in said corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said corporation, its successors and assigns.

WITNESS my hand and seal this _____ day of _____, 2002.

By: _____
 Glenn Barnes

Commonwealth of Massachusetts)
) s.s.
 County of)

Then personally appeared the above named Glenn Barnes and acknowledged the foregoing instrument to be his/her free act and deed, before me, this _____ day of _____, 2002.

 Notary Public
 My commission expires: _____

MRI-021

WITNESS my hand and seal this 28 day of May, 2002.By: Joanne Meyer

Joanne Meyer

Commonwealth of Massachusetts)

County of Suffolk) s.s.Then personally appeared the above named Joanne Meyer and acknowledged the foregoing instrument to be his/her free act and deed, before me, this 28 day of May, 2002.Nasim G. Memon

Notary Public

My commission expires: 5/1/2009